Hayley Flanagan
YOU?
Author Swipe
View article: Time to Chemotherapy and Oncofertility Counseling in Pediatric Hematology/Oncology Patients: A Single Center Retrospective Review
Time to Chemotherapy and Oncofertility Counseling in Pediatric Hematology/Oncology Patients: A Single Center Retrospective Review Open
View article: Chasing dust across glacial-interglacial North Africa through radiogenic Sr-Nd-Hf-Pb isotopes of eolian deposits off the coast of West Africa.
Chasing dust across glacial-interglacial North Africa through radiogenic Sr-Nd-Hf-Pb isotopes of eolian deposits off the coast of West Africa. Open
View article: Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia
Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia Open
View article: Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia
Shwachman–Bodian–Diamond syndrome (SBDS) protein is a direct inhibitor of protein phosphatase 2A (PP2A) activity and overexpressed in acute myeloid leukaemia Open
Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase inactivated in many cancers including acute myeloid leukaemia (AML). Activation of PP2A is emerging as a therapeutic strategy, however the mechanisms underpinning PP2A inhibit…
View article: Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors Open
Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibi…
View article: Author Index
Author Index Open